| Dr David M Dixon, PHARMD | |
|
5500 E Kellogg Dr, Wichita, KS 67218-1607 | |
| (316) 685-2221 | |
| Not Available |
| Full Name | Dr David M Dixon |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 5500 E Kellogg Dr, Wichita, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275834582 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 3364 (Wyoming) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David M Dixon, PHARMD 1898 Fort Rd, Pharmacy-119, Sheridan, WY 82801-8320 Ph: (307) 675-3581 | Dr David M Dixon, PHARMD 5500 E Kellogg Dr, Wichita, KS 67218-1607 Ph: (316) 685-2221 |
News Archive
NIH on Monday announced a pilot program that will study extremely rare diseases in people and could provide some no-cost care for study participants, the AP/San Francisco Chronicle reports.
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.
Paramount Advantage has been approved to serve eligible Medicaid recipients throughout Ohio. It was offered a statewide provider agreement by the Office of Medical Assistance (formerly the Ohio Department of Job and Family Services) to expand its service area from 18 to 88 counties.
BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
A team of researchers at the University of Washington School of Medicine has found that people who had mild COVID-19 developed a multi-layered immune response against SARS-Cov-2. The researchers detected neutralizing antibodies against the virus for at least three months after recovering from the infection.
› Verified 1 days ago
Jennifer Howard, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1515 S Clifton Ave, Suite 100, Wichita, KS 67218 Phone: 316-689-6100 | |
Dr. Gage Gregory Swanson, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1402 S Ridge Road, Wichita, KS 67209 Phone: 316-945-7455 Fax: 316-945-7457 | |
Yvonne Elias-moussa, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 N Saint Francis Ave Ste 130, Wichita, KS 67214 Phone: 316-264-3505 Fax: 316-264-0978 | |
Dr. Jacob Arthur Doeden, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3707 N Woodlawn Blvd, Wichita, KS 67220 Phone: 316-691-9134 Fax: 316-691-9138 | |
Dr. Terry Bontrager, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3601 N Webb Rd, Wichita, KS 67226 Phone: 316-630-5350 Fax: 316-630-6349 | |
Jill Baalmann, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3311 E Murdock St, Wichita, KS 67208 Phone: 316-274-8280 | |
Cindy L Leddy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-685-2221 |